Bloomage BioTechnology Corporation Limited Stock

Equities

688363

CNE100003NL9

Pharmaceuticals

End-of-day quote Shanghai S.E. 06:00:00 2024-04-29 pm EDT 5-day change 1st Jan Change
61.5 CNY +1.64% Intraday chart for Bloomage BioTechnology Corporation Limited +2.64% -8.11%
Sales 2024 * 6.97B 962M Sales 2025 * 8.45B 1.17B Capitalization 29.44B 4.07B
Net income 2024 * 862M 119M Net income 2025 * 1.17B 161M EV / Sales 2024 * 4.01 x
Net cash position 2024 * 1.51B 209M Net cash position 2025 * 1.84B 255M EV / Sales 2025 * 3.27 x
P/E ratio 2024 *
34.3 x
P/E ratio 2025 *
25.4 x
Employees 4,655
Yield 2024 *
0.91%
Yield 2025 *
1.17%
Free-Float 29.33%
More Fundamentals * Assessed data
Dynamic Chart
Bloomage BioTechnology Corporation Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Tranche Update on Bloomage BioTechnology Corporation Limited's Equity Buyback Plan announced on August 17, 2023. CI
Bloomage Biotech Names CFO MT
Bloomage Biotechnology's 2023 Profit Falls 39.5%; Misses EPS Estimates MT
Bloomage BioTechnology Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Bloomage BioTechnology Corporation Limited Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Bloomage Buys Back 8.4 Million Yuan Shares MT
Bloomage BioTechnology Corporation Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Bloomage BioTechnology Corporation Limited announces an Equity Buyback for CNY 300 million worth of its shares. CI
Bloomage BioTechnology Corporation Limited authorizes a Buyback Plan. CI
Chinese company earnings reveal lopsided economic recovery RE
Bloomage BioTechnology Corporation Limited Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Bloomage Biotech Showcases Cutting-Edge Bioactive Ingredients at International Consumer Products Expo, Expands Global Reach CI
Bloomage BioTechnology Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Yongtaiyun Chemical Logistics to Buy Local Chemical Producer For 50 Million Yuan MT
More news
1 day+1.64%
1 week+2.64%
1 month+9.59%
3 months+13.85%
6 months-19.61%
Current year-8.11%
More quotes
1 week
59.87
Extreme 59.87
63.30
1 month
52.84
Extreme 52.84
63.30
Current year
50.22
Extreme 50.22
69.48
1 year
50.22
Extreme 50.22
99.49
3 years
50.22
Extreme 50.22
314.99
5 years
50.22
Extreme 50.22
314.99
10 years
50.22
Extreme 50.22
314.99
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 02-12-31
Director of Finance/CFO 39 19-12-12
Chief Tech/Sci/R&D Officer 59 99-12-31
Members of the board TitleAgeSince
Director/Board Member 49 18-03-31
Corporate Officer/Principal 61 16-12-31
Chief Tech/Sci/R&D Officer 59 99-12-31
More insiders
Date Price Change Volume
24-04-30 61.5 +1.64% 3,030,837
24-04-29 60.51 +0.98% 2,013,186
24-04-26 59.92 +1.96% 2,383,502
24-04-25 58.77 +1.01% 1,269,070

End-of-day quote Shanghai S.E., April 29, 2024

More quotes
Bloomage Biotechnology Corp Ltd is a China-based company mainly engaged in the research and development (R&D), production and sales of hyaluronic acid and other bioactive products. The Company's products include raw material products, medical end products, functional skin care products and functional foods. The raw material products include a series of bioactive products with hyaluronic acid as the core, which are widely used in the fields of drugs, medical devices, cosmetics, functional food and general food. The medical end products are divided into medical beauty and medicine, including ophthalmic viscoelastics, medical lubricants, soft tissue fillers, medical skin protectors and others. The functional skin care products include lotion, cream, facial mask, hand mask and others. The functional foods include hyaluronic acid water, hyaluronic acid food and others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
61.5 CNY
Average target price
73.51 CNY
Spread / Average Target
+19.53%
Consensus
  1. Stock Market
  2. Equities
  3. 688363 Stock